TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Maximum NaF PET/CT Standardized Uptake Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Prostate Specific Antigen (PSA) Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Total NaF PET/CT Standardized Uptake Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FMD/VP Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Live birth or prolonged pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with breast cancer correctly identified by MARIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity and specificity of MARIA for various findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of post-operative patients correctly identified by MARIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concentration change in oxygenated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in intra-ocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough Count/Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Subjects Achieving a 20% Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural mechanisms during pain induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Opioid Requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with at least stable disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum lipid peroxidation products: isoprostanes and neuroprostaneses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebrospinal fluid (CSF) calpain-mediated cytoskeletal breakdown products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient recruitment for paired core and fine needle biopsy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presence or absence of intra or postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Serum-effect-site equilibration rate constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's Posttraumatic Stress Disorder Symptom Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aggression-Problem Behavior Frequency Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total narcotic dose administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unaided pure-tone hearing threshold measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech perception testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Questionnaire data
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Female Sexual Function Index (FSFI) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change on the composite score of apathy/avolition and anhedonia/asociality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of DANA Brief compared to ANAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in clinical laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients achieving ACR20 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective response to alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correlation between SUV and PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with further bleed
Endpoint domain: Adverse events/effects
Primary endpoint: Penile blood flow (peak systolic velocity, resistance index, pulsatility index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milligram Morphine Equivalent (MME) of Opioid Medications Utilized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flow velocity of vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: vessel diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline scar thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: occurrence of device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in time to rise from the floor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events and Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Mean level of pain during penile/vaginal intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical acceleration during sit to stand phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum voluntary isokinetic strength of quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety results
Endpoint domain: Adverse events/effects
Primary endpoint: Specific fluorescence signal of mTNF+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety from AE reporting
Endpoint domain: Adverse events/effects
Primary endpoint: LP-PLA2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in mean standard values of 18 FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meningococcal serogroup A serum bactericidal activity Geometric Mean Titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage tetanus toxoid seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of serious adverse events in expectant mothers
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion Responding Initially
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion recovered from moderate acute malnutrition (MAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal change in mid-upper arm circumference (MUAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Time to Sedation Score of 3-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3 or higher vaccine associated fever
Endpoint domain: Adverse events/effects
Primary endpoint: vaccine associated site ulceration, abscess or necrosis
Endpoint domain: Adverse events/effects
Primary endpoint: change of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in interpalpebral fissure during eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Solicited Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of blood loss in labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Self-Assessment of Severity of Vaginal Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Vaginal Superficial Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Vaginal Parabasal Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: BOLD signal responses to emotional stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Peak Expiratory Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete Healing Rate of Venous Stasis Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients with successful molecular profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extent of tissue damage in brain white matter regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall safety profile including Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Annual Bleed Rate (ABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemostatic Effectiveness of Rixubis for Participants on An On-Demand Regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hemostatic Effectiveness of Rixubis in Surgery-Perioperative and Postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Interleukin-6 (serum)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Salivary telomere length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Herpes Zoster Reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Conspicuity of occluded arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Free T4 Response Post RFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total T3 Response Post RFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Effective Bleed Resolution (All Bleed Episodes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Bleed Resolution (Spontaneous Bleed Episodes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Pain Relief (All Bleed Episodes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Pain Relief (Spontaneous Bleed Episodes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: amount of bleeding on drain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in functional connectivity (rs-fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Structural Volume Change using structural sMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Glutathione measured by magnetic resonance spectroscopy (MRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: COVID-19 mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Median time to recovery of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG of right orbicularis oculi muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Infants With Adverse Reactions After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum FGF21 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ischemic heart disease diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of cytologic quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the length of lower limbs before and after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended dose of I-131-CLR1404
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of dyspigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of papule counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of cobblestoning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Newly detected in-hospital atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity behaviour
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: functional cognitive recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroke-Free Survival Probability
Endpoint domain: Mortality/survival
Primary endpoint: sensitivity of the detector
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: positive predictive value of the detector
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of dreams related to the deceased
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with Unacceptable Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Creation of a Functional Staple Line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Virological clearance of SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in scores of Short Physical Performance Battery (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical care improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in metabolic composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Cohort Participants Attending the Last Follow-up Visit at W52
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients with HIV-1 RNA ever ≥ 50 c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Reactive Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Time Required for the HIV Testing Process
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant Satisfaction With Testing Experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression free rate (PFR) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the type of fungus in skin surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: optimal outcome
Endpoint domain: Mortality/survival
Primary endpoint: less toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Hamilton anxiety scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MiniBESTest Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fall Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Canadian Occupational Performance Measures (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Activities-Specific Balance Confidence Scale (ABC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neuroinflammation measured as IL-6 in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance on the assessment/scoring tool
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Behavioral pattern separation ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participant-reported Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biological (Objective) measures of Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Immunological effects of vaginally delivered hormonal contraception as measured by immunophenotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severe adverse event free survival
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of peripartum cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in % of youth with improved health outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Survival at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of adverse events (AE), serious adverse events (SAEs) of CLL442 on lesion free skin at Day 7
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the size of One SCCis lesion area at Day 84 from Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the Local skin reactions severity score at Day 7 or Day 84 from Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of adverse events (AE), serious adverse events (SAEs) of CLL442 on SCCis lesion at Day 84
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-emergent Changes in Body Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and Grade of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Assess safety profile of LY-CovMab
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of L-MOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Best Response (OBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vascular injury evidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Raltegravir area under the curve (AUC) 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raltegravir Cmin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent of stromal cells expressing Caveolin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Calcium Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine Calcium Excretion Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ease of fit
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PREP score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Facial bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Of Participants Who Meet The NMPP Responder Criteria At Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of terbinafine in the nail bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma terbinafine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative total fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl Meyer Upper Limb Motor Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endocrine and cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes